ERBB2 and autoimmune thrombocytopenic purpura: The rest of molecules approved in 2018 having F were baloxavir marboxil (XofluzaTM) for the treatment of influenza A and B; fostamatinib (TavalisseTM), which contains a phosphate, for chronic immune thrombocytopenia (ITP); ivosidenib (TibsovoTM), which also contains a difluorociclobutyl, for acute myeloid leukemia and cholangiocarcinoma; larotrectinib (VitrakviTM) for NTRK gene fusion–positive solid tumors; and talazoparib (TalzennaTM) for BRCA-mutated HER2-negative breast cancer (Figure 17).